News EpiWatch app detects major seizures with few false alarms An Apple Watch patient monitoring app can help people with epilepsy reduce the risk of sudden death, with high sensitivity and a low false alarm rate.
News argenx's Forte acquisition delivers coeliac trial win argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2bn acquisition of Forte, is moving into phase 3 testing for coeliac disease.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.